Ovid Therapeutics’ (OVID) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Ovid Therapeutics (NASDAQ:OVID) in a report released on Monday,Benzinga reports. They currently have a $2.00 price objective on the stock.

Other analysts also recently issued research reports about the company. Leerink Partnrs upgraded Ovid Therapeutics to a “strong-buy” rating in a research note on Monday, November 17th. Roth Capital started coverage on Ovid Therapeutics in a research report on Thursday, December 11th. They issued a “buy” rating and a $3.00 price target on the stock. Wall Street Zen cut Ovid Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Ovid Therapeutics in a research note on Wednesday, October 8th. Finally, B. Riley reiterated a “buy” rating on shares of Ovid Therapeutics in a research note on Friday, October 10th. Two research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $3.88.

Ovid Therapeutics Price Performance

NASDAQ OVID opened at $1.79 on Monday. Ovid Therapeutics has a 1 year low of $0.24 and a 1 year high of $2.01. The company has a fifty day simple moving average of $1.51 and a 200 day simple moving average of $1.09. The company has a current ratio of 4.24, a quick ratio of 4.24 and a debt-to-equity ratio of 0.28. The company has a market cap of $127.11 million, a P/E ratio of -3.57 and a beta of 0.04.

Ovid Therapeutics (NASDAQ:OVID) last released its earnings results on Wednesday, November 12th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). Ovid Therapeutics had a negative return on equity of 63.79% and a negative net margin of 550.04%.The firm had revenue of $0.13 million for the quarter, compared to analyst estimates of $0.17 million. On average, sell-side analysts predict that Ovid Therapeutics will post -0.4 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Affinity Asset Advisors LLC acquired a new stake in Ovid Therapeutics during the first quarter valued at approximately $208,000. Y Intercept Hong Kong Ltd bought a new position in shares of Ovid Therapeutics during the 2nd quarter worth approximately $53,000. Nuveen LLC acquired a new stake in Ovid Therapeutics in the 1st quarter valued at $37,000. Adage Capital Partners GP L.L.C. boosted its stake in Ovid Therapeutics by 15.0% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 1,150,000 shares of the company’s stock valued at $359,000 after buying an additional 150,000 shares in the last quarter. Finally, Velan Capital Investment Management LP grew its position in Ovid Therapeutics by 64.9% in the second quarter. Velan Capital Investment Management LP now owns 160,000 shares of the company’s stock valued at $53,000 after acquiring an additional 63,000 shares during the period. Institutional investors own 72.24% of the company’s stock.

Ovid Therapeutics News Roundup

Here are the key news stories impacting Ovid Therapeutics this week:

• Positive Sentiment: LifeSci Capital initiated coverage with an “Outperform” rating and a $4.00 price target, publishing detailed quarterly and FY EPS forecasts that show improving (but still negative) losses through FY2026 — this institutional initiation and multi-quarter model give the stock a visible analyst catalyst. LifeSci Capital initiates coverage of Ovid Therapeutics (OVID) with outperform recommendation
• Positive Sentiment: HC Wainwright & Co. reiterated a buy recommendation, reinforcing sell-side support that could help sustain investor interest and trading momentum. HC Wainwright & Co. reiterates Ovid Therapeutics (OVID) buy recommendation
• Neutral Sentiment: LifeSci’s published model projects ongoing negative EPS (examples: FY2025 ~($0.46), FY2026 ~($0.38), quarterly EPS in the ~$0.08–$0.11 loss range) — the estimates provide a roadmap for expected cash burn and timing for any positive financial inflection, but they are not evidence of immediate revenue improvement.
• Neutral Sentiment: A December short-interest report shows an apparent large “increase” but lists zero shares and a 0.0 days-to-cover figure — this looks like a data glitch and shouldn’t be treated as a meaningful change in sentiment until corrected or clarified by exchanges/brokers.

About Ovid Therapeutics

Ovid Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapies for rare neurological disorders. Founded in 2014 and headquartered in New York, the company applies a precision medicine approach to target underlying mechanisms of disease in patients with genetic conditions affecting the central nervous system. Its research platform centers on small-molecule modulators of neurotransmitter pathways to restore neural network function in disorders with high unmet medical need.

The company’s lead development candidate, OV101 (gaboxadol), is a selective extrasynaptic GABAA receptor agonist being investigated for the treatment of Angelman syndrome and Fragile X syndrome.